Uncertainties relevant to Multiple Sclerosis																									
Identifier	Priority Setting Partnership	Title	Publication Date	Source of uncertainty 1	Why is there uncertainty? 1	Shared 1	PSP ranking	What is person's age? 1	What is person's age? 2	Which types of treatments? 1	Which types of treatments? 2	Which types of treatments? 3	Which types of treatments? 4	Which types of treatments? 5	Which types of treatments? 6	Which types of treatments? 7	Which types of treatments? 8	Which types of treatments? 9	Which types of treatments? 10	Which types of treatments? 11	Original uncertainty	References to reliable up-to-date systematic reviews	Systematic reviews in preparation	Systematic reviews that need updating or extending.	Ongoing controlled trials	Which outcomes?
416565	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Are complimentary therapies effective in slowing, stopping or reversing of disability associated with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Complementary therapies											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 4 patients and 1 carer		Cui Y, Zhishun L, Miaozhena M, Lee MS, Wang J. Wu J. Acupuncture for multiple sclerosis. [Protocol]. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD008210. DOI: 10.1002/14651858.CD008210.				Change in disability; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416567	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Are supplements beneficial for people with multiple sclerosis and what supplements are most effective to treat multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Any age		Diet											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 4 patients and 1 clinician	Jagannath VA, Fedorowicz Z, Asokan GV, Robak EW, Wharmond L. Vitamin D for the management of multiple sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD008422. DOI: 10.1002/14651858.CD008422.pub2.					Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416541	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Can an accurate prognosis of multiple sclerosis be achieved as a predictor of relapses, disability, symptoms and life sty changes and response to treatment?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Diagnostic											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 22 patients, 9 carers and 8 clinicians						Progression of symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416564	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Can exercise have an effect on biomarkers associated with multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Exercise											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 carers and 2 clinicians						Change in biomarkers; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416633	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Can multiple sclerosis be prevented in relatives and family members of people with multiple sclerosis?	Oct-13	Uncertainties identified from carers' questions	No relevant systematic reviews identified			Any age		Mixed or complex											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 5 patients and 6 carers						Incidence of multiple sclerosis; adverse effects or complications; acceptability to patients or carers; health related quality of life; and costs
416634	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Can vitamin D prevent multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	Existing relevant systematic reviews are not up-to-date			Any age		Drug											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 7 patients, 3 carers and 3 clinicians		Ebe JK, Salam RA, Lassi ZS, Bhutta ZA. Food fortification with calcium and vitamin D: impact on health outcomes [Protocol]. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD010201. DOI: 10.1002/14651858.CD010201.	Jagannath VA, Fedorowicz Z, Asokan GV, Robak EW, Wharmond L. Vitamin D for the management of multiple sclerosis. Cochrane Database of Systematic Review 2010, Issue 12. Art. No.: CD008422. DOI: 10.1002/14651858.CD008422.pub2.				Incidence of multiple sclerosis; adverse effects or complications; acceptability to patients or carers; health related quality of life; and costs
416637	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Does early treatment with aggressive disease modifying drugs improve the prognosis for people with multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	Existing relevant systematic reviews are not up-to-date	Shared	6	Any age		Drug											Multiple Sclerosis Ranked 5 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 patients, 3 carers and 4 clinicians			Ge D, Xu Z, Jiang N, Zhang H, Zhou H, Wang L, Zhang S. Teriflunomide for multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD009882. DOI: 10.1002/14651858.CD009882.pub2.	Efficacy of cholecalciferol (Vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome D-Lay-MS NCT01817166 Dose-related effects of Vitamin D3 on immune responses in patients with clinically isolated syndrome CSAVID NCT01728922	Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416635	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Does supplementation of vitamin D in pregnant women and breast feeding mothers prevent multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Adult		Drug											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 1 carer and 1 clinician	Da-Regil LM, Palacios C, Amary A, Kuller R, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD008873. DOI: 10.1002/14651858.CD008873.pub2.	Abe SK, Balogun OO, Ota E, Mori R. Supplementation with multimicronutrients (excluding vitamin A) for breastfeeding women for improving outcomes for the mother and baby. [Protocol]. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD010647. DOI: 10.1002/14651858.CD010647. Dee JK, Salam RA, Lassi ZS, Bhutta ZA. Food fortification with calcium and vitamin D: impact on health outcomes [Protocol]. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD010201. DOI: 10.1002/14651858.CD010201.	Jagannath VA, Fedorowicz Z, Asokan GV, Robak EW, Wharmond L. Vitamin D for the management of multiple sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD008422. DOI: 10.1002/14651858.CD008422.pub2.				Incidence of multiple sclerosis; adverse effects or complications; acceptability to patients or carers; health related quality of life; and costs
416679	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	How and when can multi-disciplinary teams best advise and provide standard treatments for people with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Service delivery											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 4 patients and 1 carer						Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416638	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	How can a more accurate early diagnosis of multiple sclerosis be achieved?	Oct-13	Uncertainties identified from carers' questions	No relevant systematic reviews identified			Any age		Diagnostic											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 5 carers and 4 clinicians						Diagnostic accuracy of multiple sclerosis; adverse effects or complications; acceptability to patients or carers; time normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416642	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	How can magnetic resonance imaging (MRI) scanning measure the progression of multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Any age		Diagnostic	Gaucces										This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 5 patients and 1 carer	La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, Freidman S, Filippini G. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD005181. DOI: 10.1002/14651858.CD005181.pub3.		Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E. Interferon Beta for Primary Progressive Multiple Sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD009643. DOI: 10.1002/14651858.CD009643. Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E. Interferon Beta for Primary Progressive Multiple Sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD009643. DOI: 10.1002/14651858.CD009643.pub3.		Progression of symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416624	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	How can multiple sclerosis be prevented?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Shared	2	Any age		Exercise	Environmental	Mixed or complex	Diet	Education and training	Drug	Psychological therapy	Physical therapies	Complementary therapies	Vaccines and biologicals		Multiple Sclerosis Ranked 2 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 16 patients, 8 carers and 7 clinicians				Efficacy of cholecalciferol (Vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome D-Lay-MS NCT01817166 Dose-related effects of Vitamin D3 on immune responses in patients with clinically isolated syndrome CSAVID NCT01728922	Incidence of multiple sclerosis; adverse effects or complications; acceptability to patients or carers; health related quality of life; and costs
416626	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	How can people with multiple sclerosis be best supported to self manage their condition?	Oct-13	Uncertainties identified from clinicians' questions	Existing relevant systematic reviews are not up-to-date	Shared	4	Any age		Education and training											Multiple Sclerosis Ranked 4 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 4 patients, 1 carer and 5 clinicians		Khan F, Amatya B, Kesselring J. Telerehabilitation for persons with multiple sclerosis [Protocol]. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD010508. DOI: 10.1002/14651858.CD010508. Warner G, Killian L, Dobbs S, McKenzie JE, Vennel J, Packer T. Community-based self-management programs for improving participation in life activities in older adults with chronic conditions [Protocol]. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010097. DOI: 10.1002/14651858.CD010097. Coulter A, Entwistle VA, Eccles A, Ryan S, Shepperd S, Perera R. Personalised care planning for adults with chronic or long-term health conditions [Protocol]. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD010523. DOI: 10.1002/14651858.CD010523. Carson KV, Labiszewski NA, Brinn MP, Esterman AJ, Peters M, Wood-Baker R, Smith BJ. Consumer guidelines for chronic disease management [Protocol]. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010096. DOI: 10.1002/14651858.CD010096.		De Jongh T, Gurol-Urganci I, Vodopivec-Jamsek V, Car J, Atun R. Mobile phone messaging for facilitating self-management of long-term illnesses. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD007459. DOI: 10.1002/14651858.CD007459.pub2.		Examining the effects of a Telehealth self-management intervention in Multiple Sclerosis NCT01572714 Mindfulness Based Stress Reduction in Multiple Sclerosis (MS) NCT01419301	Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416668	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	How can progressive multifocal leukoencephalopathy (PML) be diagnosed and treated effectively in people with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Drug	Diagnostic										This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient						Change in multifocal leukoencephalopathy symtoms; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416677	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	How can quality of care by multiple sclerosis nurses in relation to diagnosis, treatment and prognosis of people with multiple sclerosis to be measured and improved?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Service delivery											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 patients and 2 clinicians						Service improvement measures; change in diagnosis, treatment a prognosis of people with multiple sclerosis; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416656	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is cannabis an effective treatment for multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Adult		Drug											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 patients						Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416666	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is diet effective in slowing, stopping or reversing the accumulation of disability associated with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Any age		Diet											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 3 patients, 4 carers and 4 clinicians	Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G. Dietary interventions for multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD004192. DOI: 10.1002/14651858.CD004192.pub3.					Change in disability; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416659	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is functional electrical stimulation (FES) an effective rehabilitation and for treating foot drop in people with multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Devices											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient and 2 clinicians		Claydon LS, Chesterton L, Johnson MI, Herbert GR, Bennett MI. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults [Protocol]. Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD008756. DOI: 10.1002/14651858.CD008756				Change in foot drop symptoms; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416637	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is it possible to identify the environmental factors that could be manipulated to prevent multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Diagnostic											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 carer and 2 clinicians						Incidence of multiple sclerosis; adverse effects or complications; acceptability to patients or carers; health related quality of life; and costs
416655	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is low dose naltrexone (LDN) effective in slowing, stopping or reversing the accumulation of disability associated with multiple sclerosis and managing the symptoms of multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Drug											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 11 patients, 7 carers and 5 clinicians						Progression of disability symptoms; Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416632	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is physiotherapy effective in reducing disability in people with multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects	Shared	10	Any age		Exercise	Physical therapies										Multiple Sclerosis Ranked 10 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 3 patients, 1 carer and 4 clinicians	Amatya B, Khan F, La Mantia L, Demetrios M, Wade DT. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD009974. DOI: 10.1002/14651858.CD009974.pub2.			A trial to compare the effectiveness of two rehabilitation programs for Multiple Sclerosis patients REHABMUSCLE NCT01871818 Home Exercise Intervention in persons with Multiple Sclerosis HOMS NCT01824550 Promoting Physical Activity behavior in persons with Multiple Sclerosis NCT01972207	Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416639	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is population screening for people with multiple sclerosis possible, available and effective for high risk groups?	Oct-13	Uncertainties identified from carers' questions	No relevant systematic reviews identified			Any age		Diagnostic											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 6 carers and 2 clinicians						Diagnostic accuracy of multiple sclerosis; adverse effects or complications; acceptability to patients or carers; time normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416662	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is regular exercise effective in slowing, stopping or reversing the accumulation of disability associated with multiple sclerosis and reducing the frequency of relapses?	Oct-13	Uncertainties identified from carers' questions	No relevant systematic reviews identified			Any age		Exercise											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 3 patients, 4 carers and 2 clinicians		Heine M, Rietberg MB, van Wegen EEH, Port IVD, Kwakkel G. Exercise therapy for fatigue in multiple sclerosis [Protocol]. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD009555. DOI: 10.1002/14651858.CD009555. Rietberg MB, Veerbeek J, van Wegen EEH, Gosselink R, Kwakkel G. Respiratory muscle training for multiple sclerosis [Protocol]. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD009424. DOI: 10.1002/14651858.CD009424.				Change in disability; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416657	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is stem cell therapy effective in the treatment of multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Vaccines and biologicals											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 20 patients, 5 carers and 2 clinicians						Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416661	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is the contraceptive pill effective in helping to manage multiple sclerosis?	Oct-13	Uncertainties identified from carers' questions	No relevant systematic reviews identified			Adult		Drug											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient and 2 carers						Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
416660	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is the treatment of chronic cerebrospinal venous insufficiency (CCSVI) effective for the treatment of multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Any age		Devices	Surgery										This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 16 patients, 7 carers and 2 clinicians	van Zuuren EJ, Fedorowicz Z, Pucci E, Jagannath VA, Robak EW. Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD009303. DOI: 10.1002/14651858.CD009303.pub2.					Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs

A16528	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Is vitamin D supplementation an effective disease modifying treatment for multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Shared	6	Any age		Drug											Multiple Sclerosis Ranked 6 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 3 patients,3 carers and 1 clinician		Jagannath VA, Fedorowicz Z, Avolan DJ, Robak EW, Whamond L. Vitamin D for the management of multiple sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD008422. DOI: 10.1002/14651858.CD008422.pub2.	Vitamin D as add on treatment for relapsing-remitting multiple sclerosis: a uncontrolled, randomised, double-blinded, placebo-controlled clinical trial? - 2012-004502-37 https://www.clinicaltrialsregister.eu/ctr-search/search?query=resultract_number:2012-004502-37 Efficacy of cholecalciferol (Vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome D-Lay-MS NCT01817166 Vitamin D Supplementation in Multiple Sclerosis NCT01490022		Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life and costs
A16580	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What are the appropriate criteria for starting disease modifying drugs and who should prescribe them, and is this in line with guidance on reimbursement within the NHS?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Service delivery											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from3 patients and 2 clinicians						Guidelines on when to start treatment; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life and costs
A16671	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What are the effects on carers of someone with multiple sclerosis and how can these effects be managed?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Education and training											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 carers and 6 clinicians						Impact on carers; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16674	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What are the palliative care needs of people with multiple sclerosis?	Oct-13	Uncertainties identified from carers' questions	Existing relevant systematic reviews are not up-to-date			Any age		Diagnostic											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 4 carers and 3 clinicians			Gomes B, Calanzani N, Curiale V, McCrone P, Higginson IJ. Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD007760. DOI: 10.1002/14651858.CD007760.pub2.		Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life and costs
A16644	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What are the side effects associated with different disease modifying drugs, including over the long term?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Any age		Drug											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 3 patients, 1 carer and 3 clinicians	Xie D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S. Teriflunomide for multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD008882. DOI: 10.1002/14651858.CD008882.pub2. He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S. Laquinimod for multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD010475. DOI: 10.1002/14651858.CD010475.pub2.	Shareh Saz A, Finsana BM, Hasan R, Kojan S, La Mantia L, Filippini G. Fingolimod for relapsing remitting multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD009371. DOI: 10.1002/14651858.CD009371.	Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E. Interferon Beta for Primary Progressive Multiple Sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD008643. DOI: 10.1002/14651858.CD008643.pub3.		Adverse effects or complications; Management and or change of multiple sclerosis symptoms; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16670	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What factors influence quality of life in people with multiple sclerosis and are their strategies that people with multiple sclerosis can adapt to improve quality of life?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Education and training											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 patients, 2 carers and 5 clinicians						Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life and costs
A16672	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What impact does multiple sclerosis have on sexual health and which therapeutic interventions can improve this?	Oct-13	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Adult		Exercise	Physical therapies										This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 clinician	Xiao Y, Wang J, Luo H. Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No.: CD009427. DOI: 10.1002/14651858.CD009427.pub2.						Change in sexual activity; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16676	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What impact does multiple sclerosis have on sexual relationships and which therapeutic interventions can improve this?	Oct-13	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Adult		Mixed or complex											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 carer and 2 clinicians	Xiao Y, Wang J, Luo H. Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No.: CD009427. DOI: 10.1002/14651858.CD009427.pub2.						Change in frequency and content of sexual behaviour; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16673	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What impact does multiple sclerosis have on the ability of people with multiple sclerosis, and carers, to work and what interventions are helpful?	Oct-13	Uncertainties identified from carers' questions	No relevant systematic reviews identified			Any age		Mixed or complex	Physical therapies										This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 carers and 2 clinicians						Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16569	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What information is of value to people with multiple sclerosis at different stages of their condition, and for their relatives and carers, and what method of delivery is most helpful?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Education and training											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 patient, 5 carers and 6 clinicians		O'Sullivan S, Sobel A, Khan F, Heesen C, Giordano A. Information provision for persons with multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD008757. DOI: 10.1002/14651858.CD008757. Carson KV, Labiszewski NA, Brinn MP, Esterman AJ, Peters M, Wood-Baker R, Smith BJ. Consumer guidelines for chronic disease management (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010096. DOI: 10.1002/14651858.CD010096.					Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16540	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What is the best way to measure the progression of disability in multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Diagnostic											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 clinicians						Progression of symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16543	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What is the effect of infections on disease susceptibility, relapses and progression and does treating infection have an impact on multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Diagnostic											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 clinicians						Management and or change of comorbid illness and MS symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16563	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What is the most effective and best tolerated exercise programme for people with multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Exercise											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 4 patients, 4 carers and 6 clinicians		Heine M, Rietberg MB, van Wegen EEH, Post WD, Kwakkel G. Exercise therapy for fatigue in multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD009564. DOI: 10.1002/14651858.CD009564. Rietberg MB, Veerbeek J, van Wegen EEH, Gosselink R, Kwakkel G. Respiratory muscle training for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD009424. DOI: 10.1002/14651858.CD009424.					Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16578	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What is the most valuable structure of healthcare, including care planning, involvement of multiple sclerosis specialists and community and practical support, for people with multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Service delivery											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 5 patients and 5 clinicians						Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16575	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	What tools can be developed to support decision making by people with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date			Any age		Service delivery											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 carers and 1 clinicians			Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, L?par? F, Thorsteinsdottir B, Decision aids for people facing health treatment or screening decisions (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD001431. DOI: 10.1002/14651858.CD001431.pub3.			Impact of patient impact on decision making; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16548	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which therapeutic interventions are effective for cerebellar ataxia in people with multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Any age		Environmental	Exercise	Mixed or complex	Diet		Drug	Psychological therapy	Education and training	Physical therapies	Complementary therapies	Devices	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 clinician	Sijl? Rabert M, Rigau Comas D, Fort Vanmeerhaeghe A, Santoyo Medina C, Roqu? I Figuls M, Romero-Rodr?guez D, Bonfill Cosp X. Whole-body vibration training for patients with neurodegenerative disease. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD009097. DOI: 10.1002/14651858.CD009097.pub2.		Stowe TE, Rochester L, Nell E, Skelton DA, Gallinger C. Exercise for improving balance in older people. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD004963. DOI: 10.1002/14651858.CD004963.pub3.			Change in ataxia symptoms; management and or change of MS symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16558	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which therapeutic interventions are effective for myelin repair in people with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Mixed or complex	Exercise	Environmental	Diet		Drug	Education and training	Complementary therapies	Devices	Physical therapies	Psychological therapy	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 16 patients, 5 carers and 2 clinicians		Hughes RAC, Lunn MPT, Frost C, van Schaik IN. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD010369. DOI: 10.1002/14651858.CD010369.					Change in myelin repair; Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16546	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which therapeutic interventions are effective for people with multiple sclerosis to manage bowel problems?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Any age		Exercise	Mixed or complex	Environmental	Diet		Drug	Education and training	Physical therapies	Psychological therapy	Complementary therapies	Devices	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 5 patients and 1 clinician	Omar MI, Alexander CE. Drug treatment for faecal incontinence in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD002116. DOI: 10.1002/14651858.CD002116.pub2. Maeda Y, Lauritsen S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD007659. DOI: 10.1002/14651858.CD007659.pub3. Norton C, Cody JD. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD002111. DOI: 10.1002/14651858.CD002111.pub3.						Management of bowel problems; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16551	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which therapeutic interventions are effective to improve upper limb function in people with multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified			Any age		Mixed or complex	Environmental	Exercise	Education and training	Psychological therapy	Drug	Diet	Complementary therapies	Physical therapies	Devices	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 carer and 2 clinicians						Change in movement of upper limbs; Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16545	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which therapeutic interventions are effective to prevent relapses in people with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Any age		Mixed or complex	Exercise	Environmental	Education and training	Psychological therapy	Drug	Diet	Complementary therapies	Physical therapies	Devices	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 3 patients, 2 carers and 1 clinician	Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD008921. DOI: 10.1002/14651858.CD008921.pub3. Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD008933. DOI: 10.1002/14651858.CD008933.pub2. He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S. Teriflunomide for multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD008882. DOI: 10.1002/14651858.CD008882.pub2. Wang J, Xiao Y, Luo M, Luo H. Statins for multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD008386. DOI: 10.1002/14651858.CD008386.pub3. Liu J, Wang L, Zhan SY, Xu Y. DacDuomab for relapsing remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD008127. DOI: 10.1002/14651858.CD008127.pub3. He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S. Laquinimod for multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD010475. DOI: 10.1002/14651858.CD010475.pub2. Pucci E, Giuliani G, Solari A, Sinti S, Minozzi S, Di Pietrantonj C, Galea I. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD007621. DOI: 10.1002/14651858.CD007621.pub3. He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S. Teriflunomide for multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD008882. DOI: 10.1002/14651858.CD008882.pub2.	Casetta I, Cucci G, Galea I. Plasma exchange for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD006480. DOI: 10.1002/14651858.CD006480. Shareh Saz A, Finsana BM, Hasan R, Kojan S, La Mantia L, Filippini G. Fingolimod for relapsing remitting multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD009371. DOI: 10.1002/14651858.CD009371.	La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD004678. DOI: 10.1002/14651858.CD004678.pub2. Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E. Interferon Beta for Primary Progressive Multiple Sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD008643. DOI: 10.1002/14651858.CD008643.pub3.			Time to relapse; Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16554	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which therapeutic interventions are effective to treat burning and frozen feet in people with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Environmental	Exercise	Mixed or complex	Drug	Diet	Psychological therapy	Education and training	Physical therapies	Complementary therapies	Devices	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 patients						Change in 'burning feet' symptoms; management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16553	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which therapeutic interventions are effective to treat depression in people with multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Any age		Environmental	Mixed or complex	Exercise	Education and training	Diet	Drug	Devices	Complementary therapies	Psychological therapy	Physical therapies	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 clinician	Koch MW, Gluzenberg A, Uyttenboogaart M, Mostert J, De Keyser J. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No.: CD007295. DOI: 10.1002/14651858.CD007295.pub2						Change in depression; Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16550	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which therapeutic interventions are effective to treat spasticity in people with multiple sclerosis?	Oct-13	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed importa continuing uncertainties about treatment effects			Any age		Environmental	Exercise	Mixed or complex	Diet	Drug	Education and training	Psychological therapy	Physical therapies	Devices	Complementary therapies	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 1 clinician	Amatya B, Khan F, La Mantia L, Demetrios M, Wade DT. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD009974. DOI: 10.1002/14651858.CD009974.pub2.	Pakhto RKR, Swaminathan N, Harvey LA. Passive movements for the treatment and prevention of contractures (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 9. Art. No.: CD009231. DOI: 10.1002/14651858.CD009231.					Change in spasticity; management and or change of MS symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16549	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which therapeutic interventions are effective to treat tremors in people with multiple sclerosis?	Oct-13	Uncertainties identified from carers' questions	No relevant systematic reviews identified			Any age		Mixed or complex	Exercise	Environmental	Drug	Education and training	Diet	Complementary therapies	Devices	Psychological therapy	Physical therapies	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 carers		Bruna E, Nicolini A, Quattrocchi G, Colosimo C, Filippini G, Zappia M. Alpraziolam for essential tremor (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No.: CD009681. DOI: 10.1002/14651858.CD009681.					Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs

A16652	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which therapeutic interventions are effective to treat vertigo in people with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Exercise	Mixed or complex	Environmental	Diet	Education and training	Drug	Psychological therapy	Physical therapies	Complementary therapies	Devices	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from2 patients					Change in vertigo: management and or change of MS symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life and costs
A16647	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which therapeutic interventions including catheters are effective for people with multiple sclerosis to manage bladder problems?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects			Any age		Mixed or complex	Exercise	Environmental	Education and training	Drug	Diet	Devices	Complementary therapies	Psychological therapy	Physical therapies	Vaccines and biologicals	This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 2 patients and 1 clinician	Jamison J, Meguire S, McCann J. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD004375. DOI: 10.1002/14651858.CD004375.pub3. Glazener CMA, Lapitan MCM. Urodynamic studies for management of urinary incontinence in children and adults. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD003196. DOI: 10.1002/14651858.CD003196.pub2. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD005493. DOI: 10.1002/14651858.CD005493.pub3. Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJC. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD005429. DOI: 10.1002/14651858.CD005429.pub2.	Stewart-Rupp CL, Toh SL, Lee BSB, Simpson JM, Cleary KR. Probiotics for preventing urinary tract infection in people with neurogenic bladder. [Protocol]. Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.: CD010723. DOI: 10.1002/14651858.CD010723. Utomo E, Blok B. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction [Protocol]. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD004927. DOI: 10.1002/14651858.CD004927.pub3. Ayeleke RO, Hay-Smith EJC, Omar MI. Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women [Protocol]. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD010551. DOI: 10.1002/14651858.CD010551.				Management of urinary incontinence: adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16625	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which treatments are effective for fatigue in people with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Shared	3	Any age		Mixed or complex	Environmental	Exercise	Education and training	Psychological therapy	Diet	Drug	Complementary therapies	Physical therapies	Vaccines and biologicals		Multiple Sclerosis Ranked 3 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 16 patients, 6 carers and 9 clinicians	Tejani AM, Wasdell M, Spivak R, Rowell G, Nathwani S. Carnitine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD007280. DOI: 10.1002/14651858.CD007280.pub3. Payne C, Wiffen PJ, Martin S. Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD008427. DOI: 10.1002/14651858.CD008427.pub2.	Heine M, Rietberg MB, van Wegen EEH, Port WD, Kwakkel G. Exercise therapy for fatigue in multiple sclerosis [Protocol]. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD009956. DOI: 10.1002/14651858.CD009956.			TREating FAtigue in Multiple Sclerosis: Energy conservation management TREFAMS-E ISRCTN82353628 TREating FAtigue in Multiple Sclerosis: Aerobic training TREFAMS-T ISRCTN55833774 TREating FAtigue in Multiple Sclerosis: Cognitive behavioural therapy TREFAMS-C ISRCTN56583714	Management and or change of multiple scerlosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life and costs
A16631	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which treatments are effective for pain in people with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Shared	3	Any age		Environmental	Exercise	Mixed or complex	Drug	Diet	Psychological therapy	Education and training	Physical therapies	Complementary therapies	Vaccines and biologicals		Multiple Sclerosis Ranked 3 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 4 patients and 1 carer	McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews 2013. Issue 8. Art. No.: CD006146. DOI: 10.1002/14651858.CD006146.pub2	Cai Y, Zhishun L, Marchese M, Lee MS, Wang J, Wu J. Acupuncture for multiple sclerosis [Protocol]. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD008210. DOI: 10.1002/14651858.CD008210. Accardi MC, Hallquist MN, Jensen MP, Patterson DR, Lynn S1, Montgomery GH. Clinical hypnosis for chronic pain in adults [Protocol]. Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.: CD010691. DOI: 10.1002/14651858.CD010691.	Grauste S, Derry S, Moore RA, McQuay HJ. Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD007771. DOI: 10.1002/14651858.CD007771.pub2. O'Connell NE, Wand BM, Marston L, Spencer S, DeSouza LH. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD008208. DOI: 10.1002/14651858.CD008208.pub2.			Management of pain: change in multiple scerlosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life and costs
A16630	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which treatments are effective to improve cognition in people with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Shared	3	Any age		Environmental	Mixed or complex	Exercise	Education and training	Diet	Drug	Complementary therapies	Psychological therapy	Physical therapies	Vaccines and biologicals		Multiple Sclerosis Ranked 3 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 5 patients, 3 carers and 2 clinicians	Ye D, Zhou H, Guo D, Hao Z, Wu B. Pharmacologic treatment for memory disorder in multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD008876. DOI: 10.1002/14651858.CD008876.pub2. Van Naer R, Ferguson H, Stark DL, Lincoln NB. Memory rehabilitation for people with multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD008054. DOI: 10.1002/14651858.CD008054.PUB2. Rosti-Otajärvi EM, H?m?l?inen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD009131. DOI: 10.1002/14651858.CD009131.pub3.			Walking While Talking: The Effect of Doing Two Things at Once in Individuals With Neurological Injury or Disease NCT01917903 Mindfulness Intervention for Multiple Sclerosis (MMIS) MMIS ISRCTN82353968 Randomised Controlled Trial of Cognitive Rehabilitation in Multiple Sclerosis REACTIV NCT01207856	Management and or change of multiple scerlosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life and costs
A16629	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which treatments are effective to improve mobility for people with multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Shared	7	Any age		Exercise	Mixed or complex	Environmental	Diet	Drug	Education and training	Psychological therapy	Physical therapies	Complementary therapies	Vaccines and biologicals		Multiple Sclerosis Ranked 7 This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 6 patients	Prabhu RKR, Swaminathan N, Harvey LA. Passive movements for the treatment and prevention of contractures [Protocol]. Cochrane Database of Systematic Reviews 2011, Issue 9. Art. No.: CD008231. DOI: 10.1002/14651858.CD008231.	Katalinic OM, Harvey LA, Herbert RD, Moseley AM, Lannin NA, Schurr K. Stretch for the treatment and prevention of contractures. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD007455. DOI: 10.1002/14651858.CD007455.pub2.		A trial to compare the effectiveness of two rehabilitation programs for Multiple Sclerosis patients REHABMUSCLE NCT01871618 Study on the evaluation of hippotherapy in the course of treatment for multiple sclerosis http://www.dfks.de/DRKS00005389 Home Exercise Intervention in Persons With Multiple Sclerosis HOMS NCT01824550	Management and or change of multiple scerlosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life and costs
A16623	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Which treatments are effective to slow, stop or reverse the accumulation of disability associated with Multiple Sclerosis?	Oct-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Shared	2	Any age		Mixed or complex	Exercise	Environmental	Drug	Education and training	Diet	Complementary therapies	Physical therapies	Psychological therapy	Vaccines and biologicals		Multiple Sclerosis Ranked 1. This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from 39 patients, 21 carers and 11 clinicians	Ye D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S. Teriflunomide for multiple sclerosis. Cochrane Database of Systematic Reviews 2012. Issue 12. Art. No.: CD009882. DOI: 10.1002/14651858.CD009882.pub2. La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, Freedman S, Filippini G. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database of Systematic Reviews 2012. Issue 1. Art. No.: CD005181. DOI: 10.1002/14651858.CD005181.pub3. Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G. Interferons plus glatiramer acetate for multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD007227. DOI: 10.1002/14651858.CD007227.pub3. He D, Zhou H, Han W, Zhang S. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD009130. DOI: 10.1002/14651858.CD009130.pub2. Liu L, Wang L, Zhan SY, Xia Y. Daclizumab for relapsing remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No.: CD008127. DOI: 10.1002/14651858.CD008127.pub3. Pucci E, Giuliani G, Solari A, Sinn S, Minozzi S, Di Pietrantonj C, Gaina I, Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD007621. DOI: 10.1002/14651858.CD007621.pub2 Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD008933. DOI: 10.1002/14651858.CD008933.pub2. He D, Han R, Gao A, Deng S, Chu L, Feng Z, Wu S. Laquinimod for multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD010475. DOI: 10.1002/14651858.CD010475.pub2.	Shareh Saz A, Finsama BM, Hasan R, Kojan S, La Mantia L, Filippini G. Fingolimod for relapsing-remitting multiple sclerosis [Protocol]. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD009371. DOI: 10.1002/14651858.CD009371. Casetta I, Cucci G, Galeas I. Plasma exchange for multiple sclerosis [Protocol]. Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD009480. DOI: 10.1002/14651858.CD009480. Yang C, Zhang L, Hao Z, Zeng L, Wen J. Sodium channel blockers for neuroprotection in multiple sclerosis [Protocol]. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD010422. DOI: 10.1002/14651858.CD010422.	La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 5. Art. No.: CD004678. DOI: 10.1002/14651858.CD004678.pub2. Rojas O, Romano M, Clappont A, Patrucco L, Cristiano E. Interferon Beta for Primary Progressive Multiple Sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD008643. DOI: 10.1002/14651858.CD008643.pub3			Management and or change of multiple scerlosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
A16636	James Lind Alliance Multiple Sclerosis Priority Setting Partnership	Would a vaccine to protect against epstein barr virus help to prevent multiple sclerosis?	Oct-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Vaccines and biologicals											This is an indicative uncertainty and several submissions were merged to form this one. Uncertainties identified from2 patients, 1 carer and 1 clinician						Incidence of multiple sclerosis; adverse effects or complications; acceptability to patients or carers; health related quality of life; and costs
A21197	James Lind Alliance Priority Setting Partnership on Surgery for Common Shoulder Problems	What are the outcomes of operating on shoulders in patients with Multiple Sclerosis	Sep-15	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Adult													This is a similar uncertainty was submitted by 2 patients. This is an indicative uncertainty derived from identical or similar submissions. The following are the submissions: lack of MS awareness across wards; research on MS & shoulder surgery outcomes & patients with other long term conditions cost analysis before and after sp						Using patient important measures and outcomes
A16448	Pressure Ulcer - A JLA Priority Setting Partnership	Does improving nutrition and hydration help in the healing of pressure ulcers?	Jul-13	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date			Any age		Diet											This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 3				Langer G, Knerr A, Kuss O, Behrens J, Schlömer GJ. Nutritional interventions for preventing and treating pressure ulcers. Cochrane Database of Systematic Review 2003, Issue 4. Art. No.: CD003216. DOI: 10.1002/14651858.CD003216. Sampson EL, Candy B, Jones L. Enteral tube feeding for older people with advanced dementia. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007209. DOI: 10.1002/14651858.CD007209.pub2 Stratton R J, Ek A-C, Engfer M, Moore Z, Rigby P, Wolfe R, Ellis M. Enteral nutritional support in prevention and treatment of pressure ulcers: a systematic review and meta-analysis. Ageing Research Reviews 2005; 4(2): 422-450. Reddy M, Gill S S, Kalkar S R, Wu W, Anderson P J, Rochon P A. Treatment of pressure ulcers a systematic review. JAMA 2008; 300(22): 2647-62		Ulcer healing
A15496	Pressure Ulcer - A JLA Priority Setting Partnership	For patients with Multiple Sclerosis and pressure ulcers how thickly should iodosorb be applied to aid ulcer healing?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Drug																Ulcer healing
A15475	Pressure Ulcer - A JLA Priority Setting Partnership	For people at risk of developing pressure ulcers how effective is education for lay carers in prevention of pressure ulcers including signs to look for if a pressure ulcer begins to develop?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Education and training											This submission was a variation of one which was prioritised. Priority 27This uncertainty was also suggested for the following patients and interventions:[S]. Multiple Sclerosis]						Prevention
A15422	Pressure Ulcer - A JLA Priority Setting Partnership	For people who are reliant on wheelchairs how effective is repositioning in preventing pressure ulcers?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Physical therapies											This submission was a variation of one which was prioritised. Priority 17this is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 5 This uncertainty was also suggested for the following patients and interventions:[+with Multiple Sclerosis, SL polio] [+transferring between chairs, lifting off cushions] [+How often should it be done? How does it affect ability to undertake normal activities?]		Gillespie BM, Chaboyer WP, McInnes E, Kent B, Whitty JA. Repositioning for pressure ulcer prevention in adults. Cochrane Database of Systematic Reviews 2012. Issue 7. Art. No.: CD009958. DOI: 10.1002/14651858.CD009958				Prevention
A15641	Pressure Ulcer - A JLA Priority Setting Partnership	For people with Multiple Sclerosis and pressure ulcers is posture important in relation to healing?	Jul-13	Uncertainties identified from carers' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects			Any age		Physical therapies												Moore ZEH, Cowman S. Repositioning for treating pressure ulcers. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD006898. DOI: 10.1002/14651858.CD006898.pub3		Michael S M, Porter D, Pountney T E. Tilted seat position for non-ambulant individuals with neurological and neuromuscular impairment: a systematic review. Clinical Rehabilitation 2007; 21(12): 1063-74		Ulcer Healing
A15651	Pressure Ulcer - A JLA Priority Setting Partnership	For people with Multiple Sclerosis and pressure ulcers that don't heal, what is the best type of surgical referral?	Jul-13	Uncertainties identified from carers' questions	No relevant systematic reviews identified			Any age		Service delivery	Surgery										This submission was a variation of one which was prioritised. Priority =10						Ulcer Healing
A15494	Pressure Ulcer - A JLA Priority Setting Partnership	For people with Multiple Sclerosis and pressure ulcers how effective is larval therapy in promoting ulcer healing?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Physical therapies																Ulcer healing
A15459	Pressure Ulcer - A JLA Priority Setting Partnership	For people with Multiple Sclerosis at risk of developing pressure ulcers what is the type of bed or mattresses that represents value for money to the NHS?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Devices																Value for money to the NHS
A15481	Pressure Ulcer - A JLA Priority Setting Partnership	For people with Multiple Sclerosis at risk of pressure ulcers how effective is improving hydration in the prevention of pressure ulcers?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Diet																Prevention
A15432	Pressure Ulcer - A JLA Priority Setting Partnership	For people with multiple sclerosis or spinal injury is working with specialist clinicians more effective in preventing pressure ulcers than working with generalists?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Diagnostic											This submission was a variation of one which was prioritised. Priority 5This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 2 This uncertainty was also suggested for the following patients and interventions:[+patients with Multiple Sclerosis] [+at particular risk in relation to pressure ulcers]						Prevention
A15460	Pressure Ulcer - A JLA Priority Setting Partnership	For people with pressure ulcers and Multiple Sclerosis is bed rest detrimental to mental health?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Devices											This uncertainty was also suggested for the following patients and interventions:Managing patients with limited mobility						Quality of life
A15653	Pressure Ulcer - A JLA Priority Setting Partnership	For people with pressure ulcers and Multiple Sclerosis who have been advised to keep moving, is bed rest to treat pressure ulcers safe?	Jul-13	Uncertainties identified from carers' questions	No relevant systematic reviews identified			Any age		Physical therapies											This submission was a variation of one which was prioritised. Priority 7						Adverse events

415447	Pressure Ulcer - A JLA Priority Setting Partnership	For wheelchair users with pressure ulcers, how effective is bed rest in promoting ulcer healing?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Physical therapies											This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 5 This uncertainty was also suggested for the following patients and interventions:Managing patients of limited mobility					Ulcer healing
415472	Pressure Ulcer - A JLA Priority Setting Partnership	For wheelchair usersmith Multiple Sclerosis at risk of pressure ulcers and with oedema what is the best way of preventing pressure ulcers on calves?	Jul-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects			Any age		Devices											This uncertainty was also suggested for the following patients and interventions:best way [wheelchair design/pressure relief]	McInnes E, Jammali-Blasi A, Bell-Syer SEM, Dumville JC, Cullum N. Support surfaces for pressure ulcer prevention. Cochrane Database of Systematic Reviews 2011, Issue 4. Art. No.: CD001735. DOI: 10.1002/14651858.CD001735.pub4.					Prevention
415617	Pressure Ulcer - A JLA Priority Setting Partnership	How effective are dressings in the prevention of pressure ulcers?	Jul-13	Uncertainties identified from carers' questions	No relevant systematic reviews identified			Any age		Devices											This submission was a variation of one which was prioritised. Priority 8 This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 2 This uncertainty was also suggested for the following patients and interventions: 1=hydrocolloid dressings[People with multiple sclerosis		Moore ZEH,Webster J. Dressings and topical agents for preventing pressure ulcers. Cochrane Database of Systematic Reviews 2011, Issue 10 Art. No.: CD009362. DOI: 10.1002/14651858.CD009362.			Prevention
415633	Pressure Ulcer - A JLA Priority Setting Partnership	How effective are dressings in ulcer healing?	Jul-13	Uncertainties identified from carers' questions	No relevant systematic reviews identified			Any age		Devices											This submission was a variation of one which was prioritised. Priority 8 This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 6 (3 from same source) This uncertainty was also suggested for the following patients as interventions: people with people with Multiple Scerlosis, the elderly with fragile skin, those with awkward crevasses, creases and joints. 1=Kaltostat alginate dressings; <Sorbion sound dressings; <hydrocolloid dressings; <adhesive dressings[					Ulcer Healing
415445	Pressure Ulcer - A JLA Priority Setting Partnership	How effective is negative pressure wound therapy in pressure ulcer healing?	Jul-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects			Any age		Devices											This submission was a variation of one which was prioritised. Priority7This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 3	Xie X, McGregor M, Dendukuri N. The clinical effectiveness of negative pressure wound therapy: a systematic review. Journal of Wound Care 2010; 19 (11): 490-5. PMID: 21135797		Ubbink DT,Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD001898. DOI: 10.1002/14651858.CD001898.pub2. Ubbink D T, Westerbos S J, Nelson E A, Vermeulen H. A systematic review of topical negative pressure therapy for acute and chronic wounds. British Journal of Surgery 2008; 95(6): 685-692 van den Bosquard M, de Laat E, Spauwen P, Schoonhoven L. The effectiveness of topical negative pressure in the treatment of pressure ulcers: a literature review. European Journal of Plastic Surgery 2008; 31(1): 1-7; Gregor S, Maegele M, Sauerland S, Krahn JF, Peinemann F, Lange S. Negative pressure wound therapy: a vacuum of evidence? Archives of Surgery 2008; 143(2): 189-96		Ulcer healing
415430	Pressure Ulcer - A JLA Priority Setting Partnership	How effective is patient education at preventing pressure ulcers, including information on how to self treat and at what stage of disease?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Education and training											This submission was a variation of one which was prioritised. Priority 27This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 9 This uncertainty was also suggested for the following patients and interventions:paraplegia, SB, Multiple Sclerosis					Prevention
415421	Pressure Ulcer - A JLA Priority Setting Partnership	How effective is regular turning of patients in bed at preventing pressure ulcers?	Jul-13	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date			Any age		Physical therapies											This submission was a variation of one which was prioritised. Priority 17this is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 8		Gillespie BM, Chaboyer WP, McInnes E, Kent B, Whitty JA. Repositioning for pressure ulcer prevention in adults. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD009958. DOI: 10.1002/14651858.CD009958.	Reddy M, Gill S S, Rochon P A. Preventing pressure ulcers: a systematic review. JAMA 2006;296(8):974-984.			Prevention
415424	Pressure Ulcer - A JLA Priority Setting Partnership	How frequently should people at risk of pressure ulcers change positions in order to prevent pressure ulcers?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Physical therapies											This submission was a variation of one which was prioritised. Priority 17this is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 3 This uncertainty was also suggested for the following patients and interventions: 1=wheelchair users, people with Multiple Sclerosis[					Prevention
415449	Pressure Ulcer - A JLA Priority Setting Partnership	Is staff training effective in improving pressure ulcer healing?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Education and training											This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 5 1=nurses; <GP; <carers; <nurses recruited from outside UK[					Ulcer healing
415477	Pressure Ulcer - A JLA Priority Setting Partnership	What is the best way to motivate patients to take better care of themselves?	Jul-13	Uncertainties identified from patients' questions	No relevant systematic reviews identified			Any age		Education and training											This submission was a variation of one which was prioritised. Priority 2					Prevention
415446	Pressure Ulcer - A JLA Priority Setting Partnership	What is the most effective way of keeping clean to aid pressure ulcer healing?	Jul-13	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects			Any age		Physical therapies											This is an indicative uncertainty. This or a similar uncertainty was submitted the following number of times in the survey: 3	Moore ZEH, Cowman S. Wound cleansing for pressure ulcers. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD004983. DOI: 10.1002/14651858.CD004983.pub3 Fernandez R, Griffiths R. Water for wound cleansing. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD003861. DOI: 10.1002/14651858.CD003861.pub3					Ulcer healing